Group 1 - The brain-computer interface (BCI) sector is experiencing significant growth, with companies like Neuralink and Merge Labs leading the charge in invasive and non-invasive technologies respectively [1][2] - Neuralink plans to begin large-scale production of its BCI devices in 2026, introducing a streamlined and automated surgical process that avoids traditional invasive methods [1] - Zhejiang Qiangnao Technology Co., Ltd. is emerging as a domestic unicorn in the BCI field, focusing on non-invasive technology and aiming for an IPO in mainland China or Hong Kong by 2026 [2] Group 2 - Qiangnao Technology has formed a strategic partnership with Lingyi iTech, enhancing both companies' market competitiveness and technological capabilities in the BCI and robotics sectors [2] - The global BCI market is projected to grow to approximately $12.4 billion by 2034, with a compound annual growth rate (CAGR) of 17% from 2025 to 2034, driven by technological advancements and policy support [2]

Core Viewpoint - The A-share market experienced a significant upward movement on the first trading day of 2026, with the Shanghai Composite Index rising over 1% and surpassing the 4000-point mark, driven by a surge in brain-computer interface (BCI) stocks [1] Group 1: Market Performance - The combined trading volume of the Shanghai and Shenzhen markets exceeded 1.6 trillion yuan, indicating a notable increase in market activity [1] - Several BCI-related stocks, including Sanbo Brain Science, Aipeng Medical, and others, reached the daily limit of a 20% increase [1][2] Group 2: Industry Insights - Elon Musk's recent comments regarding Neuralink's plans to mass-produce BCI devices by 2026 have sparked interest in the BCI sector, with expectations of significant advancements in technology and applications [3] - The global BCI market is projected to grow from $2.94 billion in 2025 to $12.4 billion by 2034, with a compound annual growth rate (CAGR) of 17% from 2025 to 2034 [3] - Recent research breakthroughs in medical applications such as movement recovery and communication have been reported, supported by favorable policies from the government, including separate pricing for new BCI technologies [4]

Core Viewpoint - The brain-computer interface (BCI) concept stocks surged on the first trading day of 2026 in the A-share market, driven by significant developments in the industry, including Neuralink's plans for mass production of BCI devices and supportive policies for high-end medical devices [1][3]. Group 1: Stock Performance - Multiple BCI-related stocks, including Aipeng Medical, Xiangyu Medical, and Meihua Medical, reached their daily limit up, with Aipeng Medical rising by 20% to 33.30 CNY [2][1]. - Other notable performers included Sainuo Medical and Hanwei Technology, which saw increases of 17.31% and 15.99%, respectively [2][1]. - The overall trend in the Hong Kong market mirrored that of the A-share market, with stocks like Nanjing Panda Electronics rising over 30% [2][1]. Group 2: Industry Developments - Elon Musk's Neuralink announced plans to begin large-scale production of BCI devices in 2026, signaling a significant advancement in the field [3]. - The integration of artificial intelligence in healthcare is accelerating, with 207 AI medical devices expected to be approved by 2025, highlighting the rapid technological progress [3]. - The global BCI market is projected to reach $12.4 billion by 2034, with a compound annual growth rate (CAGR) of 17% from 2025 to 2034, indicating substantial growth potential [3]. - Recent policy support, including the inclusion of implantable BCI devices in a priority approval list by the National Medical Products Administration, is expected to further enhance the commercialization process [3].

市场的热度直观地体现在成交量上。A股半日成交额达1.65万亿元，较上一交易日大幅放量超过3200亿 元。这种典型的量价齐升格局，是判断反弹能否延续的最重要基石。 从盘面结构看，今日的上涨并非普涨，而是由清晰的主线与坚实的逻辑所驱动。涨幅榜上，脑机接口、 商业航天、创新药、存储芯片以及保险板块成为最耀眼的明星。 1月5日的A股市场，为投资者献上了一份扎实的"开年礼"。主要指数放量上攻，市场情绪显著回暖，为 2026年的交易周带来了一个强劲的开局。 截至午盘，A股主要指数全线飘红。其中，上证指数强势上涨1.07%，成功收复4000点整数关口，这不 仅是技术层面的关键突破，更是市场信心转向乐观的标志。深市表现更为活跃，深证成指与创业板指分 别上涨1.87%和2.15%。而真正引领市场人气的，是半日暴涨4.05%的科创50指数，它清晰地揭示了资金 对科技创新主线的强烈追捧。 当然，市场并非全然欢腾，海南自贸区、稳定币等概念板块出现调整，这反映了资金正从旧主题向新主 线进行切换的动态过程。 展望后市，今日的放量长阳为潜在的"春季行情"奠定了良好基础。市场主线清晰，围绕 "硬科技"与"新 成长" 展开。脑机接口、商业航天 ...

Market Performance - The A-share market opened strongly on January 5, with the Shanghai Composite Index returning to the 4000-point mark after 34 trading days, closing up 1.07% [2][3] - The Shenzhen Component Index rose by 1.87%, and the ChiNext Index increased by 2.15% [2] - Over 4000 stocks in the market rose, with 98 stocks hitting the daily limit [2] Sector Performance - The brain-computer interface (BCI) sector saw a significant surge, with a half-day increase of 13.06%, leading the market [11] - Other sectors that performed well included medical devices, hyperbaric oxygen chambers, and insurance [11][12] - The A500 ETF saw a trading volume exceeding 110 billion yuan, indicating strong institutional interest [9] Investment Trends - Institutional funds have shown significant net inflows into stock ETFs since December, particularly into A500-related ETFs, indicating a bullish sentiment for the upcoming spring market [9] - The stability of the RMB exchange rate has attracted foreign capital back to A-shares and Hong Kong stocks, suggesting a new round of asset revaluation [9] - The ETF market, valued at 6 trillion yuan, is drawing increasing competition from various institutions, which may lead to product innovation and market development [9] Brain-Computer Interface Sector - The BCI sector is experiencing a pivotal moment with multiple catalysts, including Elon Musk's announcement of large-scale production of BCI devices by Neuralink in 2026 [14] - Domestic policies are increasingly supportive, with the National Medical Products Administration accelerating the review process for BCI medical devices [15] - The BCI market is expected to expand significantly due to ongoing technological advancements and supportive government policies, with a focus on clinical applications and consumer scenarios [15]

据新华社旧金山电，埃隆·马斯克2025年12月31日通过社交平台发布重磅消息，旗下脑机接口公司 Neuralink计划于2026年启动脑机接口设备大规模量产，并同步推出全自动化外科手术流程。这一规划标 志着脑机接口技术从临床验证阶段向产业化落地迈出关键一步，也成为A股人脑工程板块的强力催化， 截至1月5日上午收盘，该板块指数大涨12.56%至6245.59点，超十只概念股收获"20CM"涨停。 据Neuralink官网及马斯克公开发言内容，截至2025年9月份，该公司已完成12例脑机接口设备人体植入 手术，临床试验参与者累计使用设备时长超1.5万小时，患者可通过意念实现光标操控、文字输入甚至 机械臂辅助进食等操作，设备实际运行稳定性达标率超98%。同时，第二代手术机器人实现技术升级， 将单根电极植入时间从17秒压缩至1.5秒，整体手术时长从6小时缩短至20分钟内；成本端也实现大幅下 降，单台设备植入成本从早期百万美元级降至10万美元以内，全自动化手术落地后有望进一步下探至5 万美元区间。 《证券日报》记者注意到，A股相关上市公司早已在脑机接口赛道展开布局，从设备研发到临床应用多 维度切入，试图抢占行业发展先机 ...

脑机接口技术快速迭代升级，多家企业积极布局。当前，脑机接口技术正经历前所未有的高速迭代升 级。在信号采集端，非侵入式设备在信号质量与便携性上不断突破；在侵入式领域，柔性电极等核心器 件的研发将持续提升系统安全性、舒适度与长期稳定性。系统层面，肌电信号与脑电信号等多模态融 合，正成为提升整体稳定性与可靠性的关键趋势。与此同时，材料科学、微纳加工与芯片设计的多学科 协同创新，正持续推动核心器件性能提升与规模化生产成本下降。这些贯穿技术链条的突破性进展，共 同驱动脑机接口系统加速从实验室研究迈向实际应用，并为其从医疗级专业市场向广阔的消费级领域扩 展，并最终实现规模化商业应用提供强大技术支撑。 截至01月05日12:49，科创生物医药ETF（588250.SH）上涨4.93%，其关联指数科创生物（000683.SH） 上涨5.01%；主要成分股中，百济神州-U上涨11.46%，联影医疗上涨4.36%，益方生物-U上涨9.21%，泽 璟制药-U上涨6.74%，博瑞医药（维权）上涨7.58%。 今日早盘市场情绪积极，上证指数盘中重回4000点，科创板相关指数表现强势。盘面上，脑机接口概念 集体爆发，相关板块多只个股涨停 ...

Market Overview - The A-share market saw a strong opening on January 5, with the Shanghai Composite Index returning to 4000 points, closing at 4011.45, up 1.07% [1] - The Shenzhen Component Index rose by 1.87%, and the ChiNext Index increased by 2.15% [1] Trading Volume - The total trading volume in the Shanghai and Shenzhen markets reached 1.64 trillion yuan, an increase of 323.8 billion yuan compared to the previous trading day [3] Stock Performance - A total of 4064 stocks rose, with 99 stocks hitting the daily limit, while 1236 stocks declined [3] - The sectors that performed well included insurance, medical devices, semiconductors, and gaming, with brain-computer interface concept stocks experiencing significant gains [3] Sector Highlights Brain-Computer Interface - Brain-computer interface stocks surged, with several companies hitting the daily limit [6] - Notable performers included Xiangyu Medical, Guanhao Biological, Meihua Medical, Aipeng Medical, and Lepu Medical, all recording a 20% increase [6][7] - Elon Musk's Neuralink announced plans for large-scale production of brain-computer interface devices by December 31, 2026, which is expected to revolutionize the field by reducing invasiveness [9] Semiconductor Sector - The semiconductor sector also showed strength, with multiple stocks reaching their daily limit [10] - Key performers included Dongwei Semiconductor and *ST Tianlong, both achieving a 20% increase [11] - TSMC announced it received U.S. government approval to import chip manufacturing equipment to its Nanjing facility in 2026, which is a positive development for the sector [12] Insurance Sector - The insurance sector experienced a rally, with significant gains from major companies [13] - Xinhua Insurance rose by 7.53%, China Pacific Insurance by 6.16%, and China Life Insurance by over 5% [13][14] - The insurance industry reported a total premium income of 57.629 billion yuan for the first 11 months of 2025, a year-on-year increase of 7.6% [14]

Core Viewpoint - Gestala (Chengdu) Technology Co., Ltd. has officially launched as China's first company focused on ultrasound brain-machine interface technology, aiming to provide innovative solutions for brain disease treatment and neuroscience research through non-invasive ultrasound technology [1][2][3]. Company Overview - Gestala was co-founded by Peng Lei, former co-founder and CEO of Brain Tiger Technology, and Chen Tianqiao, founder of Shanda Group and Tianqiao Brain Science Research Institute, focusing on the innovation of ultrasound brain-machine interface technology [3][5]. - The company is located in Chengdu's Tianfu International Biological City and has also established a presence in Shanghai's Brain Intelligence World, a hub for brain-machine interface industries [3]. Technology and Applications - Gestala's ultrasound technology features non-invasive, high spatiotemporal resolution, and full-brain coverage, targeting clinical interventions for central nervous system diseases such as chronic pain, depression, and Alzheimer's disease [1][6]. - The ultrasound brain-machine interface is expected to enable precise modulation of specific brain regions without the need for surgery, allowing for innovative treatments and exploration of new targets for related brain diseases [6][8]. - The company plans to launch its first magnetic resonance-guided device for chronic pain management and initiate the NMPA registration process by the end of 2026 [8]. Clinical Collaborations and Research - Gestala has established collaborative frameworks with top hospitals such as Huashan, Xiehe, and Huaxi, aiming to deepen the synergy between industry, academia, and clinical research [8][11]. - The company has reported significant clinical intervention results in chronic pain management and depression, with effects lasting up to seven days after treatment [8]. Market Potential and Competitive Landscape - The global ultrasound brain-machine interface financing boom positions China to potentially "leapfrog" in this field, with significant investments flowing into ultrasound technology as a disruptive alternative to invasive methods [9][10]. - The ultrasound route is gaining traction due to its ability to cover 25% of the brain volume, compared to traditional invasive methods that are limited to localized areas [7][11]. - Gestala's interdisciplinary team includes experts from neuroscience, AI, ultrasound engineering, and clinical medicine, enhancing its capability for research breakthroughs and clinical applications [11].

截至1月5日午间收盘，A股98只个股涨停，74只个股首板涨停，连板梯队中以2连板、3连板个股为主，最高6连板。脑机接口成为涨停主线，三博脑科、伟 思医疗、创新医疗等数十只相关概念股批量涨停，覆盖康复设备、神经医疗、AI应用等多个细分领域；商业航天板块表现强势，中国卫通、北斗星通、中 天火箭等多股实现2连板。 | 002766.SZ 索菱股份 | 10.08% | 2连板 | 09:32:06 | 09:32:06 | 智能舱驾+无人驾驶+车联网 | | --- | --- | --- | --- | --- | --- | | 600266.S 城建发展 | 10.06% | 2连板 | 09:31:34 | 09:35:07 | 商业航天+北京国资+房地产 | | 600498.S 烽火通信 | 10.01% | 2连板 | 09:42:04 | 09:43:13 | 商业航天+光通信 | | 003009.SZ 中天火箭 | 9.99% | 2连板 | 11:15:51 | 11:29:33 | 商业航天+小型固体火箭+军贸 | | 002151.SZ 北斗星通 | 9.99% | 2连板 | 11:02 ...